Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis.

CONCLUSIONS: Vildagliptin is a promising therapeutic option for safe, effective glycemic control in type 2 diabetic patients with ESRD. PMID: 26550558 [PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/26550558?dopt=Abstract

Source: Diabetes Metab - November 12, 2015 Category: Endocrinology Authors: Mera J, Okada E, Okuda M, Ota T, Sibata S, Uchida S Tags: J Diabetes Metab Disord Source Type: research